Scarica l'app Stockscreener
9.07
2.95%
0.26
Dopo l'orario di chiusura:
9.07
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra Therapeutics’ SWOT analysis: strong MIPLYFFA launch boosts stock outlook - Investing.com
Cantor Fitzgerald Forecasts ZVRA FY2026 Earnings - Defense World
Squarepoint Ops LLC Purchases 4,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trend Tracker for (ZVRA) - news.stocktradersdaily.com
Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
ZVRAForm DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material - mx.advfn.com
BNP Paribas Financial Markets Buys New Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
ProShare Advisors LLC Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 6,877 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Deutsche Bank AG - Defense World
Zevra Therapeutics confirms board members through stockholder vote By Investing.com - Investing.com South Africa
Zevra Announces Final Results of 2025 Annual Meeting of Stockholders - The Manila Times
Zevra Announces Final Results of 2025 Annual Meeting of Stockhol - GuruFocus
Zevra Therapeutics Elects New Directors at Annual Meeting - TipRanks
Zevra Therapeutics confirms board members through stockholder vote - Investing.com
Zevra Stockholders Overwhelmingly Reject Opposition, Back Current Board with 74% Support - Stock Titan
D. E. Shaw & Co. Inc. Purchases Shares of 25,075 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Trading (ZVRA) With Integrated Risk Controls - news.stocktradersdaily.com
Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com Nigeria
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - Insider Monkey
Zevra Therapeutics’ SWOT analysis: rare disease focus drives stock potential - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Analysts - Defense World
Wall Street Zen Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Buy” - Defense World
Northern Trust Corp Buys 81,252 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26% - simplywall.st
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, - GlobeNewswire
Zevra Therapeutics ISS, Glass Lewis & Egan-Jones Recommend Zevra Stockholders Vote For Co's Director Nominees - marketscreener.com
ZVRA Receives Proxy Advisory Firms' Recommendations for Annual Meeting | ZVRA Stock News - GuruFocus
All Three Leading Proxy Advisory FirmsISS, Glass Lewis, and Egan-JonesRecommend Zevra Stockholders Vote FOR the Company's Director Nominees - The Manila Times
Q2 EPS Forecast for Zevra Therapeutics Raised by Analyst - Defense World
Price T Rowe Associates Inc. MD Purchases 6,966 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Brokers Boost Earnings Estimates for ZVRA - Defense World
What is William Blair’s Estimate for ZVRA Q1 Earnings? - Defense World
Zevra Therapeutics signals accelerated MIPLYFFA adoption and $148.3M capital infusion while expanding global reach - MSN
Q2 EPS Forecast for Zevra Therapeutics Lifted by Analyst - Defense World
Cantor Fitzgerald Reaffirms Overweight Rating for Zevra Therapeutics (NASDAQ:ZVRA) - Defense World
Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success - TipRanks
With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (ZVRA) Reports Strong Q1 Performance, Bolstered by Capital Infusion - GuruFocus
ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Ratin - GuruFocus
Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views - Benzinga
ZVRA Stock Update: Cantor Fitzgerald Reiterates Overweight Rating | ZVRA Stock News - GuruFocus
Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? - Benzinga
Zevra Therapeutics (ZVRA) Target Price Increased by Analyst | ZV - GuruFocus
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance - TipRanks
Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP - TipRanks
Zevra Therapeutics: Q1 Earnings Snapshot - CT Insider
Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Zevra Reports First Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Zevra Therapeutics Reports Strong Q1 2025 Results - TipRanks
2.13%
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):